Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ZD 0473

Known as: ZD-0473, ZD0473 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Picoplatin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
Preclinical Perspectives on Platinum Resistance
In the 30 years since the introduction of cisplatin into the clinic, laboratory studies have provided considerable information as… Expand
  • figure 1
  • figure 2
2006
2006
Synthesis, characterisation, activities, cell uptake and DNA binding of a trinuclear complex: [[trans-PtCl(NH3)]2mu-[trans-Pd(NH3)(2-hydroxypyridine)-(H2)N(CH2)6NH2)2]Cl4.
The trinuclear complex: [[trans-PtCl(NH3)](2)mu-[trans-Pd(NH(3))(2-hydroxypyridine)-(H(2)N(CH(2))(6)NH(2))(2)]Cl(4) (code named… Expand
Highly Cited
2005
Highly Cited
2005
The prediction of Raman spectra of platinum(II) anticancer drugs by density functional theory
We present the method of theoretical calculations of the Raman intensities and the simulated Raman spectra of platinum(II… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • figure 4
Highly Cited
2005
Highly Cited
2005
Synthesis, characterization, activities, cell uptake and DNA binding of trinuclear complex: [{trans-PtCl(NH(3))}(2)mu-{trans-Pt(NH(3))(2-hydroxypyridine)-(H(2)N(CH(2))(6)NH(2))(2)]Cl(4).
The trinuclear complex: [{trans-PtCl(NH(3))}(2)mu-{trans-Pt(NH(3))(2-hydroxypyridine)-(H(2)N(CH(2))(6)NH(2))(2)]Cl(4) (code named… Expand
Review
2003
Review
2003
Toxicity of platinum compounds
Since the introduction of platinum-based combination chemotherapy, particularly cisplatin, the outcome of the treatment of many… Expand
Review
2002
Review
2002
Platinum drugs in the treatment of non-small-cell lung cancer
The use of chemotherapy is considered standard therapy in patients with locally advanced non-small-cell lung cancer that cannot… Expand
  • table 1
  • table 2
  • table 3
  • table 4
Review
2001
Review
2001
Current and future potential roles of the platinum drugs in the treatment of ovarian cancer.
The discovery of cisplatin more than two decades ago was the most important therapeutic advance in the treatment of ovarian… Expand
  • table 1
  • table 2
  • figure I
  • figure 2
Highly Cited
2000
Highly Cited
2000
Mechanisms of drug resistance to the platinum complex ZD0473 in ovarian cancer cell lines.
Acquired drug resistance to the sterically hindered platinum drug ZD0473 (formerly known as JM473 and AMD473) and currently being… Expand
Highly Cited
2000
Highly Cited
2000
Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line.
Wild-type p53 is frequently mutated in late-stage ovarian cancer and has been proposed as a determinant of cisplatin… Expand
Review
1999
Review
1999
Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance.
The discovery and development of new platinum-containing anticancer drugs have represented an integral part of anticancer drug… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE